Assembly Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 65
- Market Cap
- -
- Website
- http://www.assemblybio.com
- Introduction
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
Clinical Trials
25
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 78
- Registration Number
- NCT06740474
- Locations
- 🇳🇿
New Zealand Clinical Research, Auckland, New Zealand
A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
- Conditions
- Recurrent Genital Herpes Simplex Type 2
- Interventions
- Drug: ABI-1179 Placebo
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 146
- Registration Number
- NCT06698575
- Locations
- 🇦🇺
Momentum Sunshine, Melbourne, Au, Australia
🇦🇺East Sydney Doctors, Darlinghurst, Australia
🇦🇺Royal Melbourne Hospital, Parkville, Australia
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes
- Conditions
- Recurrent Genital Herpes Simplex Type 2
- Interventions
- Drug: ABI-5366 Placebo
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 146
- Registration Number
- NCT06385327
- Locations
- 🇦🇺
East Sydney Doctors, Darlinghurst, New South Wales, Australia
🇦🇺Taylor Square Private Clinic, Surry Hills, New South Wales, Australia
🇦🇺Momentum Sunshine, Melbourne, Victoria, Australia
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 20
- Registration Number
- NCT06384131
- Locations
- 🇲🇩
ARENSIA Exploratory Medicine Chisinau, Chisinau, Moldova, Republic of
🇳🇿New Zealand Clinical Research, Auckland, New Zealand
A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: ABI-4334 TabletDrug: ABI-4334 Placebo
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 54
- Registration Number
- NCT05569941
- Locations
- 🇳🇿
New Zealand Clinical Research, Grafton, Auckland, New Zealand
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Assembly Biosciences Initiates Phase 1b Trial of Long-Acting HSV Helicase-Primase Inhibitor ABI-1179
Assembly Biosciences has dosed the first participant in the Phase 1b portion of its clinical trial evaluating ABI-1179, a long-acting herpes simplex virus helicase-primase inhibitor for recurrent genital herpes.
Assembly Biosciences' ABI-4334 Shows Potent Antiviral Activity in Phase 1b Chronic Hepatitis B Trial
Assembly Biosciences reported positive Phase 1b results for ABI-4334, a next-generation capsid assembly modulator, showing potent antiviral activity against chronic hepatitis B virus infection.
Assembly Bio Initiates Phase 1a Trial of First-in-Class Oral HDV Entry Inhibitor ABI-6250
Assembly Biosciences has dosed the first participant in a Phase 1a trial of ABI-6250, potentially the first oral therapy for chronic hepatitis delta virus infection.
Assembly Bio's ABI-5366 Shows Promise for Recurrent Genital Herpes Treatment
Assembly Biosciences reports positive Phase 1a results for ABI-5366, an HSV helicase-primase inhibitor, showing a favorable safety profile.